Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Injectable forms are clearly regulated as compounded medications
Updated phase 3 titration pathway The phase 3 schedule uses the following escalation: Weeks 1-4: 2mg weekly Weeks 5-8: 4mg weekly Weeks 9-12: 8mg weekly Week 13+: Maintenance dose (4mg, 9mg, or 12mg depending on assignment) The introduction of a 9mg dose option is interesting
Treatment is guided by a licensed provider and tailored to individual recovery needs
While these lesions are always present at birth, the extent of the lesions may not be initially appreciated due to changes in size, shape, and pigmentation over time
Dosing Comparison# Retatrutide Dosing# Based on Phase 2 trial data: Route : Once-weekly subcutaneous injection Dose range studied : 0.5 mg to 12 mg weekly Optimal dose : 12 mg weekly showed maximum efficacy in Phase 2 Titration : Gradual dose escalation over several weeks to manage GI tolerability Tirzepatide Dosing# Established FDA-approved dosing: Route : Once-weekly subcutaneous injection Starting dose : 2.5 mg weekly for 4 weeks Maintenance range : 5 mg, 10 mg, or 15 mg weekly Titration : 2.5 mg increments every 4 weeks to target dose Available formulations : Prefilled pens (Mounjaro/Zepbound) Tirzepatide's established titration protocol and prefilled pen delivery system offer practical advantages in clinical use
